⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiaryHigh fills per patient
Risk indicators are statistical patterns, not allegations. Learn more
9,704
Total Claims
$3.8M
Drug Cost
503
Beneficiaries
$7,551
Cost/Patient
Risk Score Breakdown 7/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
High fills per patient+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+92%
Cost per patient vs peers
$7,551 vs $3,933 avg
-9%
Brand preference vs peers
46.5% vs 51.2% avg
Brand vs Generic
54% generic
Brand: 4,272 claims · $3.4M
Generic: 4,922 claims · $354K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tirzepatide | 855 | $987K |
| Dulaglutide | 366 | $535K |
| Insulin Glargine,hum.Rec.Anlog | 340 | $257K |
| Insulin Aspart | 160 | $217K |
| Semaglutide | 136 | $202K |
| Insulin Lispro | 177 | $188K |
| Icosapent Ethyl | 317 | $161K |
| Dapagliflozin Propanediol | 167 | $158K |
| Icosapent Ethyl | 193 | $124K |
| Insulin Glargine,hum.Rec.Anlog | 126 | $79K |
| Insulin Glargine,hum.Rec.Anlog | 111 | $74K |
| Repaglinide | 817 | $72K |
| Finerenone | 61 | $67K |
| Linagliptin | 74 | $66K |
| Levothyroxine Sodium | 558 | $51K |
Prescribing Profile
Patient Profile
70
Avg Age
64%
Female
1.58
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About